Close Menu

Prostate Cancer

News and reporting on prostate cancer.

A multi-ancestry genome-wide association study meta-analysis uncovered 86 genetic loci associated with prostate cancer risk that researchers bundled into a genetic risk score.

The European Commission awarded a consortium of private companies and academic researchers €759,000 recently to carry out their plans.

At the Association for Molecular Pathology annual meeting, cancer researcher William Hahn talked about efforts to map cancer fitness genes at the genome scale.

Epic will access the center's liquid biopsy samples and expand its platform to in-depth characterization of cell-free fractions and circulating tumor cells.

The test will use a blood-based biopsy to detect patients with BRCA1, BRCA2, and/or ATM alterations in metastatic castration-resistant prostate cancer.

Researchers built a systematic map of protein-drug interactions to investigate the behaviors of cancer cells and the dependencies of treatment responses.

A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.

For the three months ended Sept. 30, the Belgian molecular diagnostic firm's revenues fell to $4.5 million from $4.7 million in Q3 2019.

The genomic test is covered by Medicare for all men with localized prostate cancer being considered for treatment.

The firm presented initial study results from the test, which identifies six cancers, showing overall sensitivity at 86 percent and specificity of 95 percent.

Pages

Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.

23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.

The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.

In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.